<DOC>
	<DOCNO>NCT01873339</DOCNO>
	<brief_summary>This study determine effect single repeat administration darapladib , novel , selective , orally active inhibitor lipoprotein associate phospholipase A2 ( Lp-PLA2 ) currently clinical development pharmacokinetics single oral dose midazolam , cytochrome P450 3A4 ( CYP3A4 ) probe substrate . This study investigate inductive inhibitory effect darapladib CYP3A4 metabolic pathway .</brief_summary>
	<brief_title>Pharmacokinetic Interaction Darapladib CYP 3A4 Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Darapladib</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Male female age 18 65 year age inclusive , time signing informed consent . Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test ECG . A subject alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , alkaline phosphatase bilirubin laboratory result outside reference range may include Investigator GSK Medical Monitor agree document find unlikely introduce additional risk factor interfere study procedure . Body mass index within range 1937 kilogram per meter square ( kg/m2 ) ( inclusive ) . A female subject eligible participate : nonchildbearing potential define premenopausal female tubal ligation hysterectomy postmenopausal define 12 month spontaneous amenorrhea ; childbearing potential abstinent agree use appropriate contraception method appropriate period time ( determined product label investigator ) prior start dose sufficiently minimize risk pregnancy point . Female subject must agree use contraception final followup visit ; childbearing potential samesex partner , prefer usual lifestyle . Capable give write informed consent , include compliance requirement restriction list consent form Single QTcF ( correct QT calculate use Fridericia 's formula ) &lt; 450 millisecond Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . History regular alcohol consumption within 6 month study define average weekly intake &gt; 14 drink male &gt; 7 drink female . One drink equivalent 12 g alcohol : 12 ounce ( 360 milliliter [ mL ] ) beer , 5 ounce ( 150 mL ) wine 1.5 ounce ( 45 mL ) 80 proof distil spirit . History sensitivity heparin heparininduced thrombocytopenia . History sensitivity study medication , include midazolam flumazenil , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Any contraindication midazolam flumazenil administration . Any condition , opinion investigator , present undue risk study medication , include midazolam flumazenil , procedure . Requiring use oral injectable strong CYP3A4 inhibitor use CYP3A4 inhibitor/inducers within 14 day prior dose . History anaphylaxis , anaphylactoid reaction severe allergic response . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen A positive prestudy drug/alcohol screen . A positive test HIV antibody . Pregnant female determine positive hCG test screen prior dosing . Where participation study would result donation blood blood product excess 500mL within 56 day period . Lactating female . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Unable refrain use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . Unwillingness inability follow procedure outline protocol . Subject mentally legally incapacitate . Consumption grapefruit grapefruit juice within 7 day prior first dose study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Drug interaction , healthy volunteer , SB-480848 , Lp-PLA2 , darapladib , atherosclerosis , midazolam</keyword>
</DOC>